The treatment of neuropathic pain continues to challenge clinicians, in part because of limited efficacy of available treatments and a lack of pain-specific drug targets. Mas-related G-protein-coupled receptors (Mrgprs) represent a novel family of G-protein-coupled receptors (GPCRs) that are specifically expressed in small-diameter sensory neurons. Our preliminary work suggests that some Mrgprs, in particular MrgprC, may constitute a novel inhibitory system for persistent pain. Intrathecal administration of a peptide (BAM 8-22) and a small molecule non-peptide MrgprC agonist (compound 58) both attenuated neuropathic pain in rats and in wild type mice. However, BAM 8-22 lost this analgesic action on neuropathic pain in Mrpgr mutant mice. Using complementary behavioral, electrophysiological, and molecular biological approaches, we aim to assess the therapeutic value of MrgprC as a novel target in the treatment of neuropathic pain, and importantly, to examine the cellular and molecular mechanisms underlying MrgprC-mediated pain inhibition. Specifically, Aim 1 will characterize in detail the effects of intrathecal administration of the two MrgprC agonists on tactile allodynia, mechanical hyperalgesia, heat hyperalgesia and spontaneous pain in rats after an L5 spinal nerve injury. We will then examine whether MrgprC siRNA treatment reduces the analgesic efficacy of BAM 8-22. We will also investigate whether an early intervention with BAM 8-22 prolongs attenuation of neuropathic pain, enhances morphine analgesia in neuropathic pain, and prevents postsurgical pain in rats.
In Aim 2, we will employ in vitro electrophysiological and molecular biological approaches to study the cellular and molecular mechanisms underlying MrgprC-mediated pain inhibition in the dorsal root ganglion (DRG) neurons. We will use both loss-of-function and gain-of-function strategies to determine if MrgprC activation attenuates high-voltage-gated (HVA) calcium current in DRG cells. We will further determine whether nerve injury up regulates the expression and function of MrgprC in uninjured DRG neurons.
In Aim 3 we will study the neurophysiologic basis for MrgprC-mediated pain inhibition in the central nervous system. We will conduct in vivo electrophysiological studies to determine if MrgprC agonist attenuates dorsal horn neuronal sensitization to repetitive noxious inputs and normalizes the established neuronal hyperexcitability induced by the nerve injury. We will investigate whether nerve injury alters the expression of BAM 22, an endogenous Mrgpr ligand, in spinal cord and in DRGs. We postulate that MrgprC agonists may function as anti-hyperalgesic agents during the neuropathic pain state. Because MrgprC is an ortholog to the human MrgprX1, our findings may have important implications for developing new drug leads and mechanism-based treatment strategies for managing neuropathic pain with few side effects.

Public Health Relevance

Our preliminary studies suggest that activation of an important member of Mas-related G protein-coupled receptors, MrgprC, may inhibit neuropathic pain. In this proposal, we will use complementary animal behavioral, electrophysiological, and molecular biological approaches to better assess the therapeutic utility of MrgprC agonist for the treatment of neuropathic pain and to understand the cellular and molecular mechanisms underlying the drug action. Current study may identify a new pain-specific treatment target and lead to a novel mechanism-based approach to the treatment of neuropathic pain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS070814-03
Application #
8447069
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Babcock, Debra J
Project Start
2011-04-01
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
3
Fiscal Year
2013
Total Cost
$276,955
Indirect Cost
$108,080
Name
Johns Hopkins University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Tiwari, Vinod; Guan, Yun; Raja, Srinivasa N (2014) Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats. Neurosci Biobehav Rev 45:19-27
He, Shao-Qiu; Li, Zhe; Chu, Yu-Xia et al. (2014) MrgC agonism at central terminals of primary sensory neurons inhibits neuropathic pain. Pain 155:534-44
He, S-Q; Han, L; Li, Z et al. (2014) Temporal changes in MrgC expression after spinal nerve injury. Neuroscience 261:43-51
Xu, Qian; Cheong, Yong-Kwan; He, Shao-Qiu et al. (2014) Suppression of spinal connexin 43 expression attenuates mechanical hypersensitivity in rats after an L5 spinal nerve injury. Neurosci Lett 566:194-9
Yang, F; Xu, Q; Cheong, Y-K et al. (2014) Comparison of intensity-dependent inhibition of spinal wide-dynamic range neurons by dorsal column and peripheral nerve stimulation in a rat model of neuropathic pain. Eur J Pain 18:978-88
Li, Zhe; He, Shao-Qiu; Xu, Qian et al. (2014) Activation of MrgC receptor inhibits N-type calcium channels in small-diameter primary sensory neurons in mice. Pain 155:1613-21
Guo, Ruijuan; Zhao, Yujie; Zhang, Meijuan et al. (2014) Down-regulation of Stargazin inhibits the enhanced surface delivery of ?-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor GluR1 subunit in rat dorsal horn and ameliorates postoperative pain. Anesthesiology 121:609-19
Xu, Qian; Cheong, Yong-Kwan; Yang, Fei et al. (2014) Intrathecal carbenoxolone inhibits neuropathic pain and spinal wide-dynamic range neuronal activity in rats after an L5 spinal nerve injury. Neurosci Lett 563:45-50
He, Shao-Qiu; Yang, Fei; Perez, Federico M et al. (2013) Tolerance develops to the antiallodynic effects of the peripherally acting opioid loperamide hydrochloride in nerve-injured rats. Pain 154:2477-86
Han, Liang; Ma, Chao; Liu, Qin et al. (2013) A subpopulation of nociceptors specifically linked to itch. Nat Neurosci 16:174-82

Showing the most recent 10 out of 13 publications